Custom Part 11 compliant software systems for pharmaceutical, medical device, and biotech companies — audit trails, electronic signatures, computer system validation (IQ/OQ/PQ), GAMP 5 alignment, and the technical controls FDA investigators actually look for during inspections. FreedomDev has spent 20+ years building GxP-compliant systems in Zeeland, Michigan, for companies where a 483 observation is not an inconvenience — it is a threat to their operating license.
FDA 21 CFR Part 11 is the regulation that determines whether your electronic records and electronic signatures are legally equivalent to paper records and handwritten signatures. It was finalized in 1997 and applies to every electronic record that is created, modified, maintained, archived, retrieved, or transmitted under any FDA predicate rule — 21 CFR Parts 210/211 for drug manufacturing, Part 820 for medical device quality systems, Part 58 for good laboratory practice, Part 11 itself, and dozens more. If your company stores a batch record electronically, signs a deviation report on a screen instead of on paper, or maintains electronic lab notebooks instead of bound paper notebooks, Part 11 applies. There is no opt-out. There is no materiality threshold. The regulation applies in full or it does not apply at all, and the moment you choose electronic records over paper, you have chosen to comply with every requirement in Subparts B and C.
The consequences of non-compliance are not abstract. In fiscal year 2023, the FDA issued over 1,600 warning letters across CDER, CDRH, and CBER-regulated facilities. Part 11 deficiencies are among the most commonly cited observations on FDA Form 483. Typical 483 observations include: failure to maintain computer-generated, time-stamped audit trails (Section 11.10(e)); failure to use authority checks to ensure only authorized individuals can use the system, sign, alter, or access records (Section 11.10(d)); failure to implement electronic signature controls that require two distinct identification components (Section 11.200(a)); and failure to establish and follow written policies holding individuals accountable for actions initiated under their electronic signatures (Section 11.10(j)). These are not obscure gotchas. They are the same observations FDA investigators cite year after year because companies keep making the same architectural mistakes in their software systems.
A single FDA warning letter costs public pharmaceutical companies an average of $200 million in lost market value within 30 days of publication. For private companies, a warning letter triggers import alerts, delays new product approvals, and invites follow-up inspections that consume weeks of management time. Consent decrees — the enforcement step after repeated warning letters — can shut down manufacturing lines entirely. Ranbaxy's consent decree in 2012 cost the company $500 million in fines and surrendered profit, plus years of restricted operations. Abbott Laboratories' consent decree over device quality issues lasted nearly a decade. These are the stakes when Part 11 compliance is treated as a checkbox exercise rather than a foundational system design requirement.
The root cause of most Part 11 failures is not negligence. It is architecture. Companies build or buy software systems that handle the primary business function — batch recording, lab data management, document control, deviation tracking — and then attempt to bolt on Part 11 compliance after the fact. Audit trails get implemented as application-level logging that can be modified by database administrators. Electronic signatures get implemented as simple username/password authentication without the signature manifestation requirements of Section 11.50. System validation gets treated as a testing phase at the end of development instead of a lifecycle discipline that begins with user requirements and continues through decommissioning. By the time a company discovers these gaps, the remediation cost is three to five times what it would have cost to build the system correctly from the beginning.
483 observations citing Section 11.10(e) audit trail failures — the single most common Part 11 finding during FDA inspections
Electronic signatures that fail Section 11.200(a) requirements: missing two-component authentication, no signature manifestation, no signer accountability policies
Audit trails implemented at the application layer instead of the database layer — allowing DBAs or system administrators to modify records without detection
No computer system validation documentation: missing IQ/OQ/PQ protocols, no validation master plan, no traceability from user requirements to test cases
Legacy systems running critical GxP processes with zero Part 11 controls — every electronic record they produce is legally indefensible
Off-the-shelf LIMS, EBR, and QMS platforms that claim Part 11 compliance but shift validation responsibility entirely to the customer with no guidance
Our engineers have built this exact solution for other businesses. Let's discuss your requirements.
21 CFR Part 11 is organized into three subparts. Subpart A (General Provisions) defines scope and applicability — which records and signatures fall under the rule. Subpart B (Electronic Records) establishes the technical controls required for both closed systems (Section 11.10) and open systems (Section 11.30). Subpart C (Electronic Signatures) defines signature component requirements (Section 11.100), biometric and non-biometric controls (Sections 11.200), and the legal binding of electronic signatures to records (Section 11.70). FreedomDev builds software systems that address every requirement across all three subparts, with the specific technical controls mapped to the sections of the regulation they satisfy. This is not a marketing claim — it is a traceable set of design specifications documented in validation protocols that your quality team and FDA investigators can audit independently.
For closed systems — systems where access is controlled by the people responsible for the content of the electronic records — Section 11.10 requires: validation of the system to ensure accuracy, reliability, consistent intended performance, and the ability to discern invalid or altered records; the ability to generate accurate and complete copies of records in both human-readable and electronic form; protection of records to enable their accurate and ready retrieval throughout the records retention period; limiting system access to authorized individuals; use of secure, computer-generated, time-stamped audit trails to independently record the date and time of operator entries and actions that create, modify, or delete electronic records (with audit trail documentation retained for at least as long as the subject electronic records and available for FDA review); use of operational system checks to enforce permitted sequencing of steps and events; use of authority checks to ensure that only authorized individuals can use the system, electronically sign a record, access the operation or computer system input or output device, alter a record, or perform the operation at hand; use of device (terminal) checks to determine the validity of the source of data input or operational instruction; determination that persons who develop, maintain, or use electronic record/electronic signature systems have the education, training, and experience to perform their assigned tasks; establishment of and adherence to written policies that hold individuals accountable for actions initiated under their electronic signatures; and appropriate controls over systems documentation including adequate controls over the distribution of, access to, and use of documentation for system operation and maintenance.
For open systems — where system access is not controlled by the people responsible for the record content — Section 11.30 requires all the same controls as closed systems plus additional measures such as document encryption and use of appropriate digital signature standards to ensure record authenticity, integrity, and confidentiality. Most pharmaceutical and medical device companies operate closed systems, but any cloud-hosted application, any system with third-party service provider access, and any system that transmits records over the internet must evaluate whether open system controls apply.
FreedomDev implements these controls at the database and infrastructure level, not at the application level. Audit trails are enforced through database triggers and immutable append-only tables that cannot be modified or deleted by any user, including system administrators and database administrators. Electronic signatures are cryptographically bound to the records they sign using hash chains, so any modification to a signed record is computationally detectable. Access controls are implemented through role-based permission matrices that map directly to the organizational roles defined in your SOPs. These are not configurable settings in an admin panel — they are architectural constraints that cannot be circumvented without modifying the source code, rebuilding the application, and revalidating the system.
Database-level audit trails using append-only tables with cryptographic integrity verification. Every record creation, modification, and deletion captures the operator identity, timestamp (synchronized to an NTP server with documented accuracy), the previous value, the new value, and the reason for change. Audit trail records are stored in a separate schema with independent access controls — no application user, database administrator, or system administrator can modify or delete audit entries. Retention policies are configurable per record type to match your predicate rule requirements (e.g., 3 years for batch records under 211.180, duration of the investigation for GLP study records under 58.195).
Full Part 11 electronic signature implementation including two-component identification (user ID plus password for non-biometric signatures), signature manifestation displaying the printed name of the signer, the date and time of signing, and the meaning of the signature (e.g., approval, review, verification, responsibility). Signatures are cryptographically linked to their respective records per Section 11.70 so that signatures cannot be excised, copied, or transferred to falsify another record. Continuous session signatures require at least one component at each signing; non-continuous signatures require both components for every signing event. Biometric signature support available where required.
Every system FreedomDev delivers includes a complete Computer System Validation (CSV) documentation package aligned with GAMP 5 and ISPE guidelines. This includes: a Validation Master Plan (VMP), User Requirements Specification (URS), Functional Specification (FS), Design Specification (DS), Installation Qualification (IQ) protocols and reports, Operational Qualification (OQ) protocols and reports, Performance Qualification (PQ) protocols and reports, a Requirements Traceability Matrix (RTM) linking every user requirement to its design specification, test case, and test result, and a Validation Summary Report (VSR). For GAMP 5 Category 5 (custom applications), we provide full lifecycle documentation. For Category 4 (configured products), we provide configuration documentation with risk-based testing.
Role-based access control (RBAC) matrices designed around your organizational structure and SOPs. Each user role maps to specific permitted actions: who can create records, who can modify records, who can approve records, who can sign records, who can administer user accounts, and who can view audit trails. Authority checks are enforced at both the application layer and the database layer so that bypassing the application UI does not bypass access controls. Session management includes configurable automatic logoff after inactivity, concurrent session restrictions, and failed login lockout policies.
Enforced sequencing of steps and events so that process workflows cannot be executed out of order. In a batch record context, this means Step 3 cannot be completed before Step 2 is signed off, a deviation cannot be closed before a CAPA is assigned, and a product cannot be released before all required quality checks are documented as complete. These checks are not advisory warnings — they are hard system controls that physically prevent out-of-sequence operations.
Systems are classified according to GAMP 5 software categories (Category 1 infrastructure, Category 3 non-configured, Category 4 configured, Category 5 custom) with validation effort scaled to the risk profile. We apply ICH Q9 risk management principles to determine testing depth, maintain full change control documentation for every system modification post-validation, and provide periodic review protocols so your quality team can demonstrate ongoing validated state during inspections. Every change to a validated system goes through an impact assessment, documented testing, and re-validation of affected functions before deployment to production.
Our previous system had three Part 11 observations in one inspection. FreedomDev rebuilt our electronic batch record system with proper audit trails, electronic signatures, and full IQ/OQ/PQ validation. We have been through two FDA inspections since the new system went live — zero 483 observations related to electronic records. The validation package they delivered was the most complete documentation our quality team has ever received from a software vendor.
We start by identifying every predicate rule that applies to your operation — 21 CFR Parts 210/211 for pharmaceutical manufacturing, Part 820 for medical device quality systems, Part 58 for GLP, Part 11 for electronic records, EU Annex 11 if you sell into European markets, and any industry-specific standards like ISO 13485 or ICH Q7. We audit your current systems to determine which electronic records exist, where Part 11 gaps are, and which systems carry the highest regulatory risk. Deliverable: a Part 11 Gap Analysis Report with each finding mapped to the specific section of the regulation, a risk rating (critical, major, minor), and a remediation recommendation with estimated cost and timeline.
Before writing any code, we produce the foundational validation documents. The Validation Master Plan (VMP) defines the validation strategy, roles and responsibilities, system description, regulatory requirements, acceptance criteria, and change control procedures. The User Requirements Specification (URS) captures every functional and regulatory requirement in testable terms — each requirement gets a unique identifier that traces through the entire validation lifecycle. For companies with existing validated systems, we integrate with your existing VMP rather than creating a parallel document. Every requirement in the URS traces forward to a design specification, a test case, and a test result in the Requirements Traceability Matrix.
We produce the Functional Specification (FS) and Design Specification (DS) that define exactly how the system will implement each requirement from the URS. Part 11 controls are designed into the architecture at this stage — database schema for immutable audit trails, electronic signature binding mechanism, access control framework, session management, operational system checks, and data integrity controls. For GAMP 5 Category 5 systems, the DS includes database entity-relationship diagrams, API specifications, security architecture, and infrastructure requirements. This documentation becomes the basis for IQ, OQ, and PQ protocol development.
Development proceeds in iterative cycles with validation activities running concurrently — not sequentially after development is complete. Each development sprint produces both working software and the corresponding test evidence. Unit tests are mapped to design specifications. Integration tests are mapped to functional specifications. IQ protocols verify that the system is installed correctly in the target environment with all hardware, software, and network components matching the design specification. OQ protocols verify that the system operates according to the functional specification across normal operating ranges, boundary conditions, and error conditions. PQ protocols verify that the system performs as intended in the production environment with real users, real data volumes, and real workflows.
Formal execution of IQ, OQ, and PQ protocols in the validated environment with documented evidence for every test case. Any deviations from expected results are formally documented, investigated, and resolved with documented rationale. The final Validation Summary Report (VSR) summarizes the validation approach, lists all protocols executed, documents all deviations and their resolutions, confirms traceability from URS through testing, and provides the formal recommendation for system release. The complete validation package — VMP, URS, FS, DS, IQ/OQ/PQ protocols and reports, RTM, and VSR — is delivered as a controlled document set ready for FDA inspector review.
Production deployment follows a formal release protocol with documented evidence that the production environment matches the validated environment. Post-deployment, we provide change control support — every system modification, patch, configuration change, or infrastructure update goes through an impact assessment to determine whether re-validation is required. Periodic review protocols (typically annual) verify that the system remains in a validated state, that all user accounts are current, that audit trail integrity is intact, and that the system continues to meet the requirements documented in the URS. Monthly maintenance includes security patching with validation impact assessment, performance monitoring, and audit trail storage management.
| Metric | With FreedomDev | Without |
|---|---|---|
| Audit Trail Architecture | Database-level, immutable, append-only with cryptographic integrity | Application-level logging — editable by DBAs and sys admins |
| Electronic Signature Binding | Cryptographic hash chain linking signature to record content | Username/password login treated as 'signature' with no binding |
| Validation Documentation | Complete IQ/OQ/PQ package, RTM, VMP, VSR — delivered with system | Customer responsible for all CSV documentation (vendor provides nothing) |
| GAMP 5 Alignment | Risk-based approach: Category classification drives validation scope | One-size-fits-all testing with no risk-based rationale |
| Signature Manifestation (11.50) | Printed name, date/time, meaning displayed with every signed record | Signature meaning not captured — signed records show only a name |
| Open vs. Closed System Controls | Architecture-level classification with appropriate encryption and digital signatures for open systems | No distinction between open and closed system requirements |
| Change Control Post-Validation | Formal impact assessment, re-validation of affected functions, documented evidence | Patches applied without validation impact assessment |
| FDA Inspection Readiness | Validation package structured for FDA reviewer expectations, retrievable in hours | Scramble to assemble documentation when inspection is announced |
Schedule a direct technical consultation with our senior architects.
Make your software work for you. Let's build a sensible solution.